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THE DISPARATE TREATMENT OF ADDICTION-ASSISTANCE
MEDICATIONS AND OPIATE PAIN MEDICATIONS UNDER
THE LAW: PERMITTING THE PROLIFERATION OF OPIATES
AND LIMITING ACCESS TO TREATMENT
Melissa M. Ferrara

I.

*

INTRODUCTION

Although praised for their effectiveness in managing pain, opiate pain medications have also incited debate concerning their addic1
tiveness. Our legal system, charged with striking a balance between
adequate access to pain medications and the prevention and treatment of potentially corresponding drug abuse, has severely restricted
access to addiction-assistance medications while, at the same time, has
placed much more relaxed limitations on access to opiate pain medi2
cations. Society’s view of drug addicts may explain this imbalance,
but addicts may use both types of medication either to feed or to treat
their addictions.
OxyContin is an opiate pain medication that is designed to treat
3
patients with around-the-clock moderate-to-severe pain. OxyContin
is formulated to slowly release its active ingredient, an opioid called
4
oxycodone, to relieve patients’ pain. Each tablet contains a large
quantity of oxycodone, “allow[ing] patients to take their drug less of5
ten—a distinct benefit for patients who are in chronic pain.” In
*

J.D., May 2012, Seton Hall University School of Law; B.A., 2004, American University; M.A., 2005, Rutgers University. The author wishes to thank the members of
the Seton Hall Law Review and Kate Greenwood for their help in drafting this Comment. The author would also like to thank her first friend for motivating her to
bring this issue to light.
1
See U.S. DEP’T OF HEALTH & HUMAN SERVS., SUBSTANCE ABUSE TREATMENT
ADVISORY, PUB. NO. (SMA) 06-4138, OXYCONTIN: PRESCRIPTION DRUG ABUSE-2006
REVISION
2 (2006), available at http://kap.samhsa.gov/products/brochures/
advisory/pdfs/Oxycontin-Advisory.pdf.
2
See infra Part III.A–C.
3
OxyContin—Questions and Answers, U.S. FOOD & DRUG ADMIN. (Apr. 5, 2010),
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatient
sandProviders/ucm207196.htm. [hereinafter OxyContin—Questions and Answers].
4
Id.
5
Id.
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2009, physicians wrote 6.2 million prescriptions for OxyContin, and
6
its retail sales reached three billion dollars.
When a user breaks, cuts, or chews OxyContin pills, however,
their time-release property is destroyed, and the user immediately re7
ceives the full dose of oxycodone. In 2009, 584,000 people age
8
twelve or older became “new nonmedical users” of OxyContin. A
2008 study found that 2.1% of eighth graders, 3.6% of tenth graders,
and 4.7% of twelfth graders had abused OxyContin for nonmedical
9
purposes at least once in the year prior to being surveyed. Between
2004 and 2008, emergency room visits for oxycodone products in10
creased 152%. Among persons age twelve and older, only marijuana
use is a more prevalent form of drug abuse than that of pain reliev11
ers.
The Food and Drug Administration (FDA) has approved three
drugs to assist patients in combating opiate addictions: methadone,
buprenorphine (in two formulations, Subutex and Suboxone), and
12
naltrexone.
Naltrexone is also available in an injectable, time13
release formula called Vivitrol. All three drugs treat addiction to

6

U.S. FOOD & DRUG ADMIN., ANNUAL U.S. OXYCONTIN PRESCRIPTIONS (MILLIONS)
(2010),
available
at
http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCom
mittee/UCM220954.pdf.
7
OxyContin—Questions and Answers, supra note 3.
8
U.S. DEP’T OF HEALTH & HUMAN SERVS., PUB. NO. SMA 10-4586, RESULTS FROM
THE 2009 NATIONAL SURVEY ON DRUG USE AND HEALTH: VOLUME I. SUMMARY OF
NATIONAL FINDINGS 58 (2010), available at http://www.oas.samhsa.gov/NSDUH/
2k9NSDUH/2k9ResultsP.pdf.
9
NAT’L INSTS. OF HEALTH, PRESCRIPTION AND OVER-THE-COUNTER MEDICATIONS 7
(2009), available at https://www.drugabuse.gov/sites/default/files/painmed09.pdf.
10
SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., THE DAWN REPORT:
TRENDS IN EMERGENCY DEPARTMENT VISITS INVOLVING NONMEDICAL USE OF NARCOTIC
PAIN RELIEVERS 1 (2010), available at http://oas.samhsa.gov/2k10/DAWN016/
OpioidEdHTML.pdf.
11
Id.
12
PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, ALCOHOL AND OTHER DRUG
PROBLEMS: A PUBLIC HEALTH AND PUBLIC SAFETY PRIORITY 40–41(2008), available at
http://www1.spa.american.edu/justice/
document.php?ID=2434; see also Gregory B. Collins & Mark S. McAllister, Buprenorphine Maintenance: A New Treatment for Opioid Dependence, 74 CLEVELAND CLINIC J. MED.
514, 514–16 (2007) (describing use of buprenorphine and methadone in treating
opioid dependence); Patrick G. O’Connor & David A. Fiellin, Pharmacologic Treatment
of Heroin-Dependent Patients, 133 ANNALS INTERNAL MED. 40, 44–47 (2000) (describing
use of naltrexone in treating opioid dependence).
13
Caleb Hellerman, FDA OKs Drug to Fight Opiate Addiction, CNN HEALTH CHART
BLOG (Oct. 12, 2010, 6:53 PM), http://pagingdrgupta.blogs.cnn.com/2010/
10/12/fda-oks-drug-to-fight-opiate-addiction/?iref=allsearch.
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opiates, including heroin and prescription medications like
14
OxyContin. Methadone is a long-lasting, synthetic opioid medication that prevents withdrawal, blocks the euphoric effects of heroin
15
and prescription opiates, and decreases cravings. Methadone is an
16
opioid agonist, which means that it mimics the effects of the abused
17
opiate. “Buprenorphine is an opioid partial agonist,” which means
that it can produce the effects of an agonist (i.e., euphoria and respiratory depression), but its maximum agonistic effect is much less
18
than that of a full agonist like methadone. Buprenorphine also reduces cravings, blocks the effect of heroin and other opiates, reduces
adverse symptoms associated with withdrawal, and has a long dura19
tion of action. Unlike methadone or buprenorphine, naltrexone is
an opioid antagonist, which means that it blocks receptors in the
brain to prevent users from obtaining the euphoric effects of heroin
20
and other opiates. By depriving the patient of the abused opiate’s
21
effects, naltrexone works to break the habit of opiate addiction.
In 2006, recognizing the need to combat opiate addiction, the
World Health Organization (WHO) added methadone and bupren22
orphine to its Fourteenth Model List of Essential Medicines. Although physicians in the United Kingdom, France, and Australia have
utilized addiction-assistance medications as an effective tool to treat
23
opiate dependence, the same has not been true in the United

14

PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 39.
David A. Fiellin & Patrick G. O’Connor, New Federal Initiatives to Enhance the
Medical Treatment of Opioid Dependence, 137 ANNALS INTERNAL MED. 688, 688 (2002);
O’Connor & Fiellin, supra note 12, at 45–46; NAT’L INSTS. OF HEALTH, NIH PUB. NO.
99-4180, PRINCIPLES OF DRUG ADDICTION TREATMENT: A RESEARCH-BASED GUIDE 37 (2d.
ed. 2009), available at https://www.drugabuse.gov/sites/default/files/podat_0.pdf.
16
See U.S. DEP’T OF HEALTH & HUMAN SERVS., THE DASIS REPORT: PLANNED
METHADONE TREATMENT FOR HEROIN ADMISSIONS 1 (2003), available at
http://www.samhsa.gov/data/2k3/MethadoneHtx/methadoneHtx.pdf.
17
GOODMAN AND GILMAN’S MANUAL OF PHARMACOLOGY AND THERAPEUTICS 14
(Laurence Brunton, et al. eds., 2008).
18
About Buprenorphine Therapy, CSAT BUPRENORPHINE INFO. CENTER,
http://buprenorphine.samhsa.gov/about.html (last visited March 12, 2012).
19
Hendree E. Jones, Practical Considerations for the Clinical Use of Buprenorphine,
SCI. & PRAC. PERSP., Aug. 2004, at 4, 4–5, available at http://www.naabt.org/
documents/Practical_Conciderations%20.pdf.
20
PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 41.
21
NAT’L INST. OF HEALTH, supra note 15, at 40.
22
WORLD HEALTH ORG., WHO MODEL LIST OF ESSENTIAL MEDICINES 21 (14th ed.
2005), available at http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf.
23
Fiellin & O’Connor, supra note 15, at 691 (describing opioid agonist maintenance treatment in the United Kingdom, Australia, and France).
15
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States. In the United States, an imbalanced legal structure permits
the wide dissemination of highly addictive pain medications, but limits access to addiction-assistance medications. This imbalance explains the underutilization of addiction-assistance medications in the
United States.
This Comment argues that the incongruent legal treatment of
addiction-assistance medications in comparison to opiate pain medications is a flawed system because it increases access to opiates while
limiting access to addiction assistance. This Comment will use
OxyContin as an illustration of all opiate pain medications because it
is so widely abused and because of the controversy surrounding the
25
product’s design. Part II will explain the legal framework under
which all medications fall, highlighting in particular the statutes that
are applicable to this analysis. Part III will discuss the statutes and
regulations that apply to OxyContin, methadone, and buprenorphine, focusing on important differences and incongruities between
the two legal structures. Notably, both methadone and buprenorphine are regulated more heavily than OxyContin despite the fact
that methadone is in the same controlled substance schedule as
OxyContin and buprenorphine is in a less restrictive controlled substance schedule. Part IV will recommend changes that will ameliorate the disparate treatment of these medications, addressing the
supply and demand sides of this problem and highlighting the Washington state model, which requires physicians to refer patients to pain
specialists once their pain requires a certain dosage of an opiate pain
reliever, as an example. This Comment does not advocate restricting
access to pain medications for those in legitimate need, but it does
question the logic of permitting the wide dissemination of drugs like
OxyContin and, simultaneously, severely restricting access to methadone and buprenorphine.

24
James L. Nolan, Jr., Harm Reduction and the American Difference: Drug Treatment
and Problem-Solving Courts in Comparative Perspective, 13 J. HEALTH CARE L. & POL’Y 31,
36–37 (2010).
25
Cf. Jennifer Corbett Dooren, FDA Approves Reformulated OxyContin, WALL ST. J.
(Apr.
6,
2010),
http://online.wsj.com/article/
SB10001424052702304620304575166391268139192.html (reporting that the FDA
approved a reformulated version of OxyContin on April 5, 2010, which is supposed
to be more tamper resistant).
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II. THE REGULATORY FRAMEWORK FOR PRESCRIPTION MEDICATIONS
Federal and state laws make up the legal framework for all medi26
cations. The two pertinent federal statutes are the Food, Drug and
27
28
Cosmetic Act (FDCA) and the Controlled Substances Act (CSA).
State controls on physician licensing also contribute to the legal
29
structure. In addition, many states have adopted the Uniform Con30
trolled Substances Act (UCSA) and/or a law, like the Pain Relief
31
32
Act, guarding the right to pain medication.
33
In 1938, Congress passed the FDCA. The FDA administers the
34
FDCA, and it is responsible for determining the safe and effective
35
use of prescription medications. Drug research, testing, and clinical
36
trials make up the drug approval process. The process begins with
the drug manufacturer conducting various laboratory and animal
37
38
tests. Next, the manufacturer conducts testing with humans. After
the tests, the manufacturer submits a New Drug Application, which
includes the test results, to the Secretary of Health and Human Ser39
40
vices. The FDA’s physicians and scientists review the application.
26

David E. Joranson & Aaron Gilson, Controlled Substances, Medical Practice, and the
Law, in PSYCHIATRIC PRACTICE UNDER FIRE: THE INFLUENCE OF GOVERNMENT, THE MEDIA
AND SPECIAL INTERESTS ON SOMATIC THERAPIES 173, 175–90 (Harold I. Schwartz ed.,
1994).
27
21 U.S.C §§ 301–399d (2006).
28
Id. §§ 801–971.
29
See generally Becoming a Physician: Medical Licensure, AM. MED. ASSOC.,
http://www.ama-assn.org/ama/pub/education-careers/becomingphysician/medical-licensure.shtml (last updated April 17, 2011).
30
UNIF. CONTROLLED SUBSTANCES ACT (1994).
31
The Pain Relief Act, 24 J. L. MED. & ETHICS 317(1996).
32
See generally Database of State Statutes, Regulations, and Other Official Governmental
Policies, PAIN & POL’Y STUD. GROUP, http://www.painpolicy.wisc.edu/matrix.htm (last
updated Dec. 7, 2011) (containing a matrix of all state statutes, regulations, and
guidelines concerning controlled substances and pain)[hereinafter Database of State
Statutes].
33
Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended in scattered sections of 21 U.S.C.).
34
21 U.S.C. § 301 (2006).
35
See id. § 355(a).
36
Kimani Paul-Emile, Making Sense of Drug Regulation: A Theory for Drug Control Policy, 19 CORNELL J.L. & PUB. POL’Y 691, 698 (2010).
37
What Is the Approval Process for a New Prescription Drug?, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.htm (last
visited Jan. 27, 2012) [hereinafter What Is the Approval Process for a New Prescription
Drug?].
38
Id.
39
Id.; § 355(b).
40
What Is the Approval Process for a New Prescription Drug?, supra note 37.
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If they determine that the drug’s benefits outweigh its known risks
and that the drug can be manufactured in a way that ensures a quality
product, then the FDA approves the drug and the manufacturer can
41
market it in the United States. As of 2007, the FDA is authorized to
require an applicant to adopt a Risk Evaluation and Mitigation Strategy (REMS) if the FDA determines that such a strategy is necessary to
42
ensure that the drug’s benefits outweigh its risks.
Congress passed the Comprehensive Drug Abuse Prevention and
43
Control Act of 1970 as the first universal drug legislation. Title II of
44
the Act is the CSA, which classifies controlled substances into five
45
Schedule placement depends on a controlled subschedules.
stance’s legitimate medical value, the risk for abuse, and its potential
46
addictiveness. A controlled substance’s schedule dictates the degree
47
of restriction with which the FDA treats each substance. Schedule I
controlled substances, like heroin and lysergic acid diethylamide
48
(LSD), are strictly prohibited, while Schedule V controlled substances are the least restricted and include commonly used painkill49
ers like Codeine.
The Drug Enforcement Administration (DEA), part of the Unit50
ed States Department of Justice, administers the CSA. The DEA
must consult with the FDA before scheduling a drug as a controlled
51
substance. Because the FDA’s recommendations on the scientific
and medical value of a drug are binding on the DEA, the DEA cannot
52
schedule a drug if the FDA recommends otherwise.
The DEA may establish total quantity and production quotas for
53
Schedule I and Schedule II drugs. When establishing quotas, the
41

Id.
21 U.S.C. § 355-1(a) (2006).
43
1970-1975, U.S. DRUG ENFORCEMENT ADMIN., http://www.justice.gov/dea/
pubs/history/deahistory_01.htm (last visited Nov. 9, 2011).
44
21 U.S.C. §§ 801–971 (2006).
45
§ 812(a).
46
Paul-Emile, supra note 36, at 698; see § 812(b).
47
See § 812(b); Dispensing of Controlled Substances to Residents at Long Term
Care Facilities, 75 Fed. Reg. 37,463, 37,464 (June 29, 2010).
48
§ 812(c).
49
See Dispensing of Controlled Substances to Residents at Long Term Care Facilities, 75 Fed. Reg. 37,464 (June 29, 2010).
50
Exec. Order No. 11,727, 38 Fed. Reg. 18,357 (July 6, 1973).
51
PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 719 (3d
ed. 2007).
52
21 U.S.C. § 811(b) (2006).
53
Id. § 826; Western Fher Laboratories v. Levi, 529 F.2d 325, 327 (1st Cir. 1976).
42
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Attorney General considers, but is not limited to, the disposal rates of
the manufacturer, national trends of disposal, inventory and production cycles, the drug’s stability, the availability of raw materials used in
the manufacture of the drug, and emergencies, such as strikes and
54
fires.
Anyone who wishes to dispense controlled substances, such as a
55
physician, a hospital, or a pharmacy, must register with the DEA. To
be eligible to obtain a registration, a practitioner must be licensed or
otherwise authorized to dispense controlled substances under the
56
laws of the state in which he or she practices. DEA registration and
the CSA permit the practitioner to dispense controlled substances to
57
the extent that they are authorized under the law.
The CSA also requires registrants to maintain a current and
complete record of each controlled substance that they have dis58
pensed. The drug’s schedule determines whether the physician may
provide an oral prescription to a pharmacist or whether a written
59
prescription is required. If a practitioner violates any requirements
under the CSA or if his or her license has been suspended, revoked
or denied, the Attorney General can take legal action to suspend or
60
revoke the practitioner’s DEA registration.
In addition to the federal statutory structure for medications,
state laws and licensing requirements create the legal framework for
61
prescribers. In general, each state has a medical board charged with
setting physician, hospital, and pharmacy licensing requirements and
with evaluating applicants to ensure that they meet those require62
ments. Licensure requirements vary from state to state, but they
generally include meeting certain education and training requirements, passing an examination demonstrating competency to practice medicine, and a background check to verify professional compe63
tence, ethics, and character.

54

§ 826(c).
Id. § 822(a); 21 C.F.R. § 1301.11 (2012).
56
Id. § 823(f)
57
§ 822(b).
58
Id. § 827(a).
59
See id. § 829.
60
Id. § 824.
61
Joranson & Gilson, supra note 26, at 175.
62
Dispensing of Controlled Substances to Residents at Long Term Care Facilities, 75 Fed. Reg. 37,467 (June 29, 2010).
63
Id.
55
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Many states have adopted, in whole or in part, two model statutes in the drug-regulation area—the Uniform Controlled Substances
64
Act (UCSA) and the Pain Relief Act. The National Conference of
Commissioners on Uniform State Statutes drafted the UCSA in 1994
to maintain uniformity between the laws of the states and the federal
government and to provide guidance on how the federal and state
65
laws should interact for the best use of government resources. The
UCSA also “provides law enforcement tools to improve investigative
efforts and provides for education and training programs relating to
66
the drug abuse problem.” The UCSA scheduling is identical to that
67
contained in the CSA. The UCSA provides states with discretion,
including setting penalties for violations of the Act; requiring manufacturers, distributors, and dispensers of controlled substances to register with the appropriate state authority; setting the parameters for
obtaining registration; and setting the grounds for suspension or rev68
ocation of registration.
69
The Pain Relief Act is another model statute. Its goals are to
protect physicians who prescribe pain medications from prosecution
or disciplinary or licensing actions and to protect patients’ access to
70
pain medication. The Act does not protect practitioners who fail to
maintain required records, write false prescriptions, or illegally divert
71
medications for non-medical uses. The Act refers to addiction and
chemical dependency once, but it does so in the context of protect72
ing access rather than expressing concern for abuse. The Act provides that all patients are entitled to the same access to pain relief
medication “regardless of the patient’s prior or current chemical de73
pendency or addiction.” The drafters, however, afford states the
discretion to appoint an appropriate state body to develop standards
and procedures “for the application of this Act to the care and treat74
ment of chemically dependent individuals.”

64
65
66
67
68
69
70
71
72
73
74

See Database of State Statutes, supra note 32.
UNIF. CONTROLLED SUBSTANCES ACT Prefatory Note, at 1 (1994).
Id. Prefatory Note, at 2.
See id. §§ 201–212.
Id. §§ 301–305, 401.
The Pain Relief Act, 24 J. L. MED. & ETHICS 317(1996).
See id. at 318.
Id. (see Sec. 4.a. –d.).
Id. (see Sec. 3.3).
Id.
Id.
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III. COMPARING OXYCONTIN’S REGULATORY FRAMEWORK WITH THAT
FOR METHADONE AND BUPRENORPHINE
Federal regulations of methadone and buprenorphine are much
75
more stringent than those of OxyContin. Although the DEA has
scheduled methadone and OxyContin identically, and despite the
DEA scheduling buprenorphine in a less restrictive schedule than
OxyContin, the addiction-assistance medications are subject to dosage restrictions, patient limitations, and special physician registration
76
requirements that do not apply to OxyContin and its prescribers.
A. OxyContin
77

The FDA initially approved OxyContin on December 12, 1995.
78
In 2010, the FDA approved a new formulation of OxyContin. The
new pill was designed to resist efforts to circumvent its controlled79
release property. The effectiveness of the new design remains un80
known. Like methadone, OxyContin is a Schedule II drug under
81
the CSA. Although Schedule II drugs have a high potential for
abuse, they also have a “currently accepted medical use in treatment
in the United States or a currently accepted medical use with severe
82
restrictions.” Severe psychological or physical dependence may re83
sult from the abuse of a Schedule II controlled substance. The CSA
provides that, except in emergency situations, a pharmacy may only
dispense a Schedule II controlled substance pursuant to a practition84
er-signed written prescription.

75

See infra Part III.A–C.
See infra Part III.A–C.
77
OxyContin: Balancing Risks and Benefits: Hearing Before the S. Comm. on Health,
Educ., Labor and Pensions, 107th Cong. 14 (2002) (statement of John K. Jenkins, Dir.,
Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Admin.) [hereinafter Jenkins].
78
See Letter from Bob A. Rappaport, Dir. Div. of Anesthesia and Analgesia Products, Center for Drug Evaluation and Research, to Craig Landau, Chief Med. Officer
& Vice President, Clinical, Med. & Reg. Affairs, Purdue Pharma, (Apr. 5, 2010),
available
at
http://www.accessdata.fda.gov/
drugsatfda_docs/appletter/2010/022272s000ltr.pdf.
79
See id.
80
See New Tamper-Resistant OxyContin Tablets to be Released August 2010, NAT’L ASS’N
BOARDS PHARMACY (Aug. 19, 2010, 11:04 AM), http://www.nabp.net/news/newtamper-resistant-oxycontin-tablets-to-be-released-august-2010/.
81
Jenkins, supra note 77.
82
21 U.S.C. § 812(b)(2)(A)–(C) (2006).
83
§ 812(b)(2)(C).
84
Id. § 829(a).
76
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In contrast to the addiction-assistance medications discussed be85
low, prescribers of OxyContin must comply with only one regulatory
86
limitation. It is a supply limitation, and an exception in the regula87
tion loosens it. Although the CSA prohibits the refill of prescrip88
tions for Schedule II controlled substances, the DEA has issued a
regulation that allows practitioners to issue multiple prescriptions at a
time, which means that a physician can provide a patient with up to
89
three thirty-day prescriptions of OxyContin at once.
Despite
OxyContin’s and methadone’s identical classification, this exception
90
does not apply to methadone.
Although methadone and OxyContin are both Schedule II substances and although buprenorphine is in a less restrictive classification than both, only the addiction-assistance medications require a
91
practitioner to meet a special DEA registration requirement. Therefore, any practitioner who has registered with the DEA can prescribe
OxyContin, and no practitioner is under any obligation to meet any
training requirements to prescribe OxyContin.
The OxyContin REMS requires that the manufacturer send
training materials, including information on patient selection, dos92
ing, risks, and addiction, to healthcare professionals. The training
93
packet includes an OxyContin Education Confirmation Form. The
manufacturer maintains a list of the prescribers who submit the
94
form. While a prescriber’s signature on the form confirms that he
or she “read the REMS Education Materials for OxyContin and understand[s] the major risks associated with OxyContin and how to
appropriately select and educate patients to whom OxyContin is prescribed,” failure to complete the form does not affect a physician’s
95
ability to prescribe the drug. The OxyContin REMS also requires
the drug manufacturer to provide prescribing information and a
medication guide with each bottle of the drug and imposes labeling
85

See infra Part III.B–C.
See 21 C.F.R. § 1306.12 (2012).
87
See id.
88
§ 829(a).
89
§ 1306.12.
90
See id.
91
21 U.S.C. § 823(g)(1) (2006).
92
PURDUE PHARMA, OXYCONTIN RISK EVALUATION MITIGATION STRATEGY 2 (2010),
http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformati
onforPatientsandProviders/UCM220990.pdf.
93
Id. at 3.
94
Id.
95
Id. at 35.
86
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96

requirements. The REMS also advises prescribing physicians to in97
form patients to flush unused tablets down the toilet. Patients also
98
receive this information in the eight-page medication guide. Accordingly, unlike addiction-assistance medications, any physician can
prescribe OxyContin without meeting any training or DEA registration requirements and without ever certifying that he or she read the
training materials that the REMS obligates the manufacturer to provide.
The only other limitation placed on OxyContin relates to the
99
DEA’s quota powers for Schedule I and II controlled substances.
100
Oxycodone is the opiate pain reliever that OxyContin contains.
Until 2011, the DEA had increased the quota for oxycodone every
101
year since 2002 with the exception of 2008, when the quota re102
mained unchanged from 2007.
In 2010, the quota for oxycodone
103
available for sale was 105,500,000 grams. In 2002, the quota for oxycodone available for sale was 34,482,000 grams, which means that
over that eight-year period, the DEA permitted a 206% increase in
104
the oxycodone quota. The DEA decreased the quota to 98,000,000
105
grams in 2011.
OxyContin is available in seven dosage strengths,
106
Although
ranging from ten milligram to eighty milligram tablets.
oxycodone is used in other medications, if one assumes, for illustrative purposes, that OxyContin was the only medication manufactured
from oxycodone, the 2010 quota would permit the production of between 15,050,000,000 (for ten milligram tablets) and 1,881,250,000
96
Id. at 1–2; see also PURDUE PHARMA, MEDICATION GUIDE (2010),
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf.
97
PURDUE PHARMA, supra note 96.
98
Id.
99
See 21 C.F.R. § 1315.30 (2012).
100
OxyContin—Questions and Answers, supra note 3.
101
See
Federal
Register
Notices,
OFFICE
DIVERSION
CONTROL,
http://www.deadiversion.usdoj.gov/fed_regs/index.html (last visited, Jan. 26,
2012)(listing the quotas for each year under a separate link).
102
Compare Controlled Substances: Final Revised Aggregate Production Quotas
for 2007, 72 Fed. Reg. 48,616, 48,618 (Aug. 24, 2007), with Controlled Substances:
Final Revised Aggregate Production Quotas for 2008, 73 Fed. Reg. 66,939, 66,941
(Nov. 12, 2008).
103
Controlled Substances: Final Revised Aggregate Production Quotas for 2010,
75 Fed. Reg. 55,828, 55,830 (Sept. 14, 2010).
104
Controlled Substances: Final Revised Aggregate Production Quotas for 2002,
67 Fed. Reg. 59,313, 59,315 (Sept. 20, 2002).
105
Controlled Substances: Final Revised Aggregate Production Quotas for 2011,
76 Fed. Reg. 77,016, 77,019 (Dec. 9, 2011).
106
PURDUE PHARMA, supra note 92, at 29.
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(for eighty milligram tablets) tablets of OxyContin. Although the
DEA has the power to limit OxyContin production through its quota
authority, the DEA has dramatically increased the availability of oxycodone over the last eight years. While this may be warranted for legitimate users, the increase remains in stark contrast to the limited
107
availability of addiction-assistance medications.
Additionally, while
the rate of marijuana dependence or abuse has remained steady over
the last eight years, the number of people suffering from painreliever dependence or abuse has increased from 1.5 million to 1.9
108
million over the same period of time.
B. Methadone
The FDA approved methadone in late 1972 to treat opiate addic109
tion.
“Methadone is to an addict what insulin is to a diabetic, for
both drugs enable an otherwise ill individual to function as a healthy,
110
Although
normal human being contributing his part to society.”
not a cure for opiate addiction, when used as a short-term therapy or
111
in a “long-term maintenance treatment program,” methadone “improve[s] treatment retention, decreas[es] relapse, and ameliorat[es]
the other social, legal, and medical problems often associated with
112
illicit drug misuse.”
Despite the identical controlled substance classification of
113
OxyContin and methadone, the regulatory and statutory treatment
of methadone is far more restrictive than OxyContin’s, particularly in
114
The patients each drug is designed to
regards to patients’ access.
serve—drug addicts versus pain sufferers—may explain this disparity.
115
In light of the rates of OxyContin abuse, however, some portion of

107

See infra Part.III.B.–C.
U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 8, at 6.
109
INST. OF MED., FEDERAL REGULATION OF METHADONE TREATMENT 1 (Richard A.
Rettig & Adam Yarmolinsky eds.,1995).
110
Andrew G. Bucaro & Mary Williams Cazalas, Methadone: Treatment and Control of
Narcotic Addiction, 44 TUL. L. REV. 14, 31 (1969).
111
21 U.S.C. § 802(29) (2006) (“The term ‘maintenance treatment’ means the
dispensing, for a period in excess of twenty-one days, of a narcotic drug in the treatment of an individual for dependence upon heroin or other morphine-like drugs.”).
112
Richard C. Boldt, Introduction: Obstacles to the Development and Use of Pharmacotherapies for Addiction, 13 J. HEALTH CARE L. & POL’Y 1, 3 (2010) (citing Karen L. Sees
et al., Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial, 283 JAMA 1303, 1309 (2000)).
113
See 21 U.S.C. § 812(c) (2006).
114
See infra Part.III.B.–C.
115
See supra text accompanying notes 7–11.
108
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OxyContin prescriptions are, in fact, provided to drug addicts. Accordingly, a distinction based on patient needs alone fails to fully justify the radical disparities.
The Narcotic Addiction Treatment Act of 1974 and the Drug
Addiction Treatment Act of 2000 amended the CSA, updating approval and licensing procedures for practitioners who treat opiate
116
addiction with medication.
On January 21, 2001, the Substance
Abuse and Mental Health Services Administration (SAMHSA) of the
Department of Health and Human Services promulgated regulations
concerning the treatment of opiate dependence with addiction117
assistance medications.
The regulations define the registration requirements for practitioners and the accreditation and certificationbased system for facilities that dispense methadone, referred to as
118
Opioid Treatment Programs (OTPs), which SAMHSA oversees.
The Administrator of SAMHSA has delegated some oversight responsibilities to its Center for Substance Abuse Treatment (CSAT) and,
119
within CSAT, to the Division of Pharmacologic Therapies.
The
120
regulations did not disturb the states’ authority to regulate OTPs.
Accordingly, a tripartite system of oversight between the states,
121
SAMHSA, and the DEA remained in place after the amendments.
1.

Opioid Treatment Programs

Unlike OxyContin, which is available from any doctor’s office,
methadone is only available from OTPs, which are subject to heavy
122
federal regulation and frequent local zoning controversies.
The
process to qualify as an OTP consists of two parts—accreditation and
123
124
Accreditation is a peer-review process.
Reviewers
certification.
evaluate the OTP’s pending application pursuant to SAMHSA’s OTP
116

JOSEPH T. RANNAZZISI & MARK W. CAVERLY, DRUG ENFORCEMENT ADMIN.,
PRACTITIONER’S
MANUAL
23
(2006),
available
at
http://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf;
see Narcotic Addiction Treatment Act of 1974, Pub. L. No. 93-281, 88 Stat. 124; 21
U.S.C. § 823(g) (2006).
117
42 C.F.R. §§ 8.1–8.34 (2011).
118
§ 8.11.
119
Opioid Treatment Regulation, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
http://www.dpt.samhsa.gov/regulations/regindex.aspx (last visited Mar. 12, 2012)
[hereinafter Opioid Treatment Regulation]; see also § 8.11(f)(2) (providing discretion to
certain entities).
120
See § 8.11(f).
121
See § 8.11(f)(2).
122
PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 40.
123
42 C.F.R. § 8.4 (2011).
124
Id.
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standards and visit the facility to verify that it meets accreditation re125
quirements.
After accreditation, “SAMHSA uses the accreditation
results along with other data to determine whether the program is
qualified to carry out treatment under the standards in the regula126
tions.” SAMHSA then certifies the programs that qualify, at which
127
time these programs can dispense methadone.
In addition to the federally-required accreditation and certifica128
tion process, an OTP must comply with local zoning restrictions.
129
Zoning is an exercise of the state’s police power. A relatively recent
line of cases in Pennsylvania illustrates the tension between local zon130
In New Directions Treating initiatives and anti-discrimination laws.
ment Services v. City of Reading, the Third Circuit invalidated a zoning
statute that provided specific limitations on methadone facilities,
finding that the statute violated the Americans with Disabilities Act
131
132
(ADA) and the Rehabilitation Act.
The Pennsylvania statute at
issue in New Directions restricted the location of the methadone facility, specifically its proximity to residential housing, schools, parks,
playgrounds, churches or other establishments of regular religious
133
worship, and child-care facilities.
The statute also provided that a
local governing body could opt out of the proximity restriction by
majority vote, allowing a methadone facility to operate closer to a re134
stricted building than provided in the statute. The City of Reading
(the “City”) did not opt out of the proximity requirements and denied a permit to New Directions Treatment Services (“New Direc135
tions”), a methadone treatment facility.
New Directions appealed
136
the denial.
The district court granted the City’s motion for sum137
mary judgment.

125

Id.
Opioid Treatment Regulation, supra note 119.
127
Id.
128
See New Directions Treatment Servs. v. City of Reading, 490 F.3d 293, 298 (3d
Cir. 2007).
129
See Village of Euclid v. Ambler Realty Co., 272 U.S. 365, 387 (1926).
130
See New Directions, 490 F.3d 293; see also Freedom Healthcare Servs. v. Zoning
Hearing Bd. of New Castle, 983 A.2d 1286 (Pa. Commw. Ct. 2009).
131
New Directions, 490 F.3d 293.
132
53 PA. CONS. STAT ANN. § 10621 (West 1999).
133
New Directions, 490 F.3d at 299.
134
Id.
135
Id. at 299.
136
Id. at 300.
137
Id.
126
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New Directions then appealed to the Third Circuit, which held
that providing local governments the ability to waive the proximity
restrictions did not mitigate the fact that the law singled out methadone facilities—and therefore methadone patients—and that this
rendered the statute facially discriminatory under the ADA and the
138
Rehabilitation Act. If, however, the methadone facility posed a significant risk to the population, the ADA and the Rehabilitation Act
139
would not prohibit the zoning restrictions. Relying on objective evidence, like links between crime rates and methadone clinics, the
United States Court of Appeals for the Third Circuit found no evidence to support the safety concerns that the City and its residents
raised; the court found that the denial more closely resembled “dep140
rivations based on prejudice, stereotypes, or unfounded fear.” Accordingly, the significant risk doctrine did not validate the zoning
141
statute.
The Third Circuit also evaluated whether the City violated the
Fourteenth Amendment’s guarantee of equal protection in its appli142
cation of the statute.
The court remanded the claim, instructing
the district court to apply the rational basis test and to determine: (1)
whether the issues raised that were unrelated to the nature of the facility or its clientele, such as loitering, noise, or parking, differentiated this facility from other permitted uses, and (2) whether such a distinction would permit denying the permit or whether the purported
143
legitimate reasons for the denial were pretextual.
Two years later in Freedom Healthcare Services v. Zoning Hearing
Board of the City of New Castle, the Pennsylvania Commonwealth Court
relied on New Directions to find that a zoning board had improperly
144
Here, the board
denied a zoning permit to a methadone facility.
based the denial on the lack of parking; the danger to the health,
safety, and welfare of the neighborhood that the facility would present because of the applicant’s “noticeable inexperience” in running
a methadone facility; the increase in traffic; and the presence of chil-

138

Id. at 305.
New Directions, 490 F.3d at 305.
140
Id. at 307 (citing School Bd. of Nassau Cnty. v. Arline, 480 U.S. 273, 287
(1987)).
141
Id.
142
Id. at 310.
143
Id. at 312.
144
Freedom Healthcare Servs. v. Zoning Hearing Bd. of New Castle, 983 A.2d
1286 (Pa. Commw. Ct. 2009).
139
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145

dren in the area of the facility.
Freedom Healthcare Services argued that the board improperly applied the zoning ordinance and
146
that the zoning permit application met all parking requirements.
The board asserted that Freedom Healthcare Services had the burden of producing sufficient evidence to demonstrate that it would
not harm the health and safety of the community based on the facili147
ty’s hours, patients, and the traffic it would produce. Although the
court found these concerns valid, it held that the ordinance did not
place restrictions on the hours or number of patients of a medical
clinic and it would, therefore, be inappropriate to apply them to this
148
zoning permit application.
While courts have found that zoning statutes cannot discriminate against methadone facilities, facility locations remain controversial. In Salem, Massachusetts, the zoning board rewrote its zoning
ordinance to tighten its definition of “medical facility” and attempted
to add language imposing additional restrictions on drug-dispensing
facilities while leaving other medical offices unaffected all based on
149
rumors of a pending methadone treatment facility application. Potential and current neighbors of methadone facilities have raised ob150
jections to the location of treatment centers from Boise, Idaho, to
151
152
Somers Point, New Jersey, to Columbia, Tennessee, voicing concerns over crime rates, parking, traffic, and exposing children to ad153
dicts.
2.

Physician and Dosage Requirements

In addition to the facility restrictions, practitioners who wish to
dispense methadone must meet special DEA registration require145

Id. at 1289–90, 1292.
Id. at 1290.
147
Id. at 1291.
148
Id. at 1292.
149
Bella Travaglini, Salem Clinic Proposal Prompts Rewrite of Zoning Amendment,
(June
29,
2010,
12:05
PM),
http://www.boston.com/
BOSTON.COM
yourtown/news/salem/2010/06/salem_ordinance.html.
150
Kiersten Throndsen, Methadone Clinic Has Some Upset Over Location, KBOI2.COM
(Nov. 17, 2009, 10:55 PM), http://www.kboi2.com/news/70345467.html.
151
Shaun Smith, Narrow Street, Methadone Clinic Raise Safety Concerns for West Cedar
Avenue, SHORE NEWS TODAY (Sept. 15, 2010), http://www.shorenewstoday.com/
index.php/mainland-/mainland/4305-narrow-street-methadone-clinic-raise-safetyconcerns-for-west-cedar-avenue.html.
152
Carley Gordon, Neighborhood Outraged over Proposed Clinic, WSMV (Oct. 27,
2011, 3:19 PM), http://www.wsmv.com/story/15894787/neighborhood-outragedover-proposed-clinic.
153
See sources cited supra notes 149–52.
146
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ments beyond those required for OxyContin, despite the fact that
both are Schedule II controlled substances. In addition to the nor155
mal registration requirements, a practitioner who wishes to dispense methadone must obtain an additional, separate registration
156
number from the DEA.
The practitioner must also obtain the approval of and register with both the CSAT and the appropriate state
157
methadone authority.
Methadone patients also face dosage and other types of restrictions that are much more severe than the ninety-day supply restriction on OxyContin, including limits on when patients can take
methadone home and how much can be prescribed during the
158
course of their treatment.
A practitioner cannot prescribe more
than thirty milligrams of methadone as an initial dose and more than
forty milligrams on the first day of treatment, unless the practitioner
documents that forty milligrams did not suppress withdrawal symp159
toms.
A single take-home dose of methadone is permitted for the
160
time when the methadone clinic is closed. In addition, the regulations list criteria that help physicians evaluate patients for unsuper161
vised methadone use. If a patient meets the criteria, the regulations
permit the patient to take a single dose per week outside the clinic
162
during the first ninety days of treatment. During the second ninety
days of treatment, the patient is permitted to take two doses per week
163
for use outside the clinic. In the third ninety days, this quantity in164
The patient is permitted a maxicreases to three doses per week.
mum supply of six take-home doses per week for the remainder of
165
the first year of treatment. After the first year of continuous treat166
ment, the patient may receive a two-week supply at a time. After the
second year of continuous treatment, the patient may reach the max-

154

21 U.S.C. § 823(g)(1) (2006).
For a detailed discussion of the normal registration requirements, see supra
Part II.
156
§ 823(g)(1).
157
RANNAZZISI & CAVERLY, supra note 116, at 23.
158
42 C.F.R. § 8.12(h) (2011).
159
§ 8.12(h)(3)(ii).
160
§ 8.12(h)(4).
161
Id.
162
Id.
163
Id.
164
Id.
165
42 C.F.R. § 8.12(h)(4) (2011).
166
Id.
155
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167

imum take-home amount—a one-month supply. The patient must
168
continue to make monthly visits. If a patient requires an exception
to the take-home structure, for example, because of employment,
disability, or transportation hardships, the physician must submit to
SAMHSA and (where applicable) to the state methadone authority
an “exception request” for approval to deviate from these re169
strictions.
In sum, localities create targeted zoning restrictions that are discriminatory and not based on empirical evidence to impede methadone facilities, governing agencies proffer no evidence of special
skills or complexities in methadone treatment to substantiate additional physician registration requirements, and methadone dosage
restrictions are draconian. In contrast to the rigid regulatory structure for methadone, the OxyContin regulations do not require practitioners to prescribe the medication from a federally-certified facility
separate from their offices but does require them to comply with just
one dosing limitation, which has an exception that permits a practi170
tioner to provide three prescriptions at once. In light of the similarities between the chemical compositions of these two drugs, their
incongruent treatment under the law seems unfounded. Furthermore, in light of the increase in opiate prescription abuse, the regulations appear to encourage the continued use of opiate pain medications while vigorously limiting access to methadone, which treats the
very addiction that the OxyContin regulations facilitate.
C. Buprenorphine
Physicians in the United States have used low doses of bupren171
orphine since 1985 for the treatment of pain. In October 2002, the
FDA approved two buprenorphine products containing high doses of
the drug—Suboxone and Subutex—for the treatment of opiate ad172
diction.
In its higher dosage, buprenorphine reduces craving,
blocks the effect of heroin and other opiates, reduces adverse symptoms associated with withdrawal, and remains active for a longer du173
ration.
167

Id.
Id.
169
42 C.F.R. § 8.11(h) (2011).
170
See supra Part III.A.
171
See DRUG ENFORCEMENT ADMIN., BUPRENORPHINE (2011), available
http://www.deadiversion.usdoj.gov/drugs_concern/buprenorphine.pdf.
172
Id.
173
Jones, supra note 19, at 4–5.
168

at
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Following the recommendation of the Department of Health
and Human Services, the DEA classified buprenorphine and the
174
products containing the drug as Schedule III controlled substances.
Schedule III drugs have a lower potential for abuse than Schedule I
or II drugs, have a currently accepted medical use, and abuse of these
drugs “may lead to moderate or low physical dependence or high
175
psychological dependence.”
Unlike methadone and similarly to OxyContin, practitioners can
prescribe Suboxone and Subutex outside the heavily regulated OTP
176
environment. Unlike OxyContin and similarly to methadone, however, to prescribe buprenorphine, practitioners must meet special
registration criteria and the number of patients they can treat is lim177
ited.
As with methadone, a practitioner who wishes to prescribe
buprenorphine must obtain an additional registration with the DEA
178
on an annual basis. Because buprenorphine is a Schedule III controlled substance rather than a Schedule II controlled substance,
however, the CSA permits practitioners to waive the additional regis179
tration requirement if they are able to meet certain criteria.
A practitioner who seeks waiver must first submit a written noti180
fication of intent to the Secretary of the DHHS. The written notification must include the practitioner’s DEA registration number and
a certification that the practitioner meets two of the following criteria: is licensed under state law and (1) is board certified in addiction
psychiatry from the American Board of Medical Specialties, or (2) has
an addiction certification from the American Society of Addiction
Medicine, or (3) is board certified in addiction medicine from the
American Osteopathic Association, or (4) has other specialized training either through coursework or participation in clinical trials of the
181
drug. The practitioner must also certify that he or she has the capacity to refer addiction treatment patients for other appropriate
counseling and services and that he or she will not exceed the regu182
lated patient limits.
Practitioners are limited to treating thirty pa-

174
175
176
177
178
179
180
181
182

Id. at 4; see also 21 U.S.C. § 812(c) shed. III (2006).
§ 812(b)(3)(A)–(C).
PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 41.
See id.
See 21 U.S.C. § 823(g)(2) (2006).
Id.
§ 823(g)(2)(B)–(D).
§§ 823(g)(2)(B)(i), 823(g)(2)(G)(ii).
§ 823(g)(2)(B)(ii).
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tients in the first year, with a maximum of one hundred patients
183
thereafter.
The CSAT then evaluates whether the practitioner meets the
waiver requirements. If so, the CSAT refers the waiver request to the
184
DEA.
If the DEA approves the practitioner’s request, the practi185
At this time, the
tioner receives a Unique Identification Number.
186
practitioner may dispense buprenorphine. Over a two-year period,
the practitioner must meet stringent record-keeping requirements,
187
including keeping records of receipt, storage, and distribution,
188
none of which are required to dispense OxyContin.
Practitioners may dispense Schedule III controlled substances
189
In contrast to every other
with a written or oral prescription.
Schedule III medication, only physicians can prescribe buprenor190
phine. The physician must include his or her regular DEA registration number and Unique Identification Number on each prescrip191
tion.
The physician must also maintain a record of each
192
prescription for a period of at least two years. As of June 2009, the
SAMHSA and the DEA had approved nearly 15,700 physicians to provide office-based buprenorphine treatment, about 13,150 to treat up
to thirty patients, and about 2500 to treat up to one hundred pa193
tients.
The rules provide for an exception to the registration or registration waiver requirement to permit a practitioner to administer, but
not prescribe, buprenorphine in an emergency situation in which a
patient is experiencing acute withdrawal symptoms and in which it
would be impractical to require a practitioner to meet the registra194
tion requirement.
Under the so-called “three-day rule,” a practitioner may administer three daily doses of the medication to last for a
single seventy-two-hour period, permitting the practitioner a period

183

§ 823(g)(2)(B)(iii).
RANNAZZISI & CAVERLY, supra note 116, at 23.
185
Id.
186
Id.
187
Id.
188
See supra Part III.A.
189
21 U.S.C. § 829(b) (2006).
190
Robert J. Roose et al., Nurse Practitioner and Physician Assistant Interest in Prescribing Buprenorphine, 34 J. SUBSTANCE ABUSE TREATMENT 456, 458 (2008).
191
21 C.F.R. § 1306.05(a)–(b) (2011).
192
§ 1304.04(a).
193
DRUG ENFORCEMENT ADMIN., supra note 171.
194
21 C.F.R. § 1306.07(b) (2012).
184
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to arrange for the patient’s treatment in a detoxification or
196
maintenance program. The practitioner may not renew or extend
197
the seventy-two hour period.
In sum, addiction-assistance medications’ regulations require
special DEA registration, and practitioner training and impose facility
restrictions, dosage limits, and patient limits. These restrictions stand
in stark contrast to the controls imposed on OxyContin—a drug that
is abused and classified in a schedule above buprenorphine, yet is
limited only through a quota that has steadily increased over an eightyear period and through restrictions on prescription refills.
IV. RECOMMENDED REFORMS
The results of the SAMHSA 2009 annual survey on national drug
use highlight two reforms that are required to address OxyContin
abuse—proper medication disposal and physician oversight and/or
198
training. The survey breaks down the reported sources of prescription pain relievers based on the users’ most recent non-medical uses
and found that 70.2% of users obtained the drug from a friend or
relative, 17.6% obtained the drug from one doctor, 4.8% obtained
the drug from a drug dealer or stranger, and 0.4% bought the drug
199
on the Internet. Additionally, eighty percent of the friends or relatives who provided the drug to the users obtained the drug from just
200
one doctor. These statistics highlight two issues on the supply side
of this equation: (1) the need to appropriately advise patients on how
to dispose of their medications; and (2) the need for heightened requirements on practitioners who prescribe opiate pain medications.

195

See 21 U.S.C. § 802(30) (2006) (“The term ‘detoxification treatment’ means
the dispensing, for a period not in excess of one hundred and eighty days, of a narcotic drug in decreasing doses to an individual in order to alleviate adverse physiological or psychological effects incident to withdrawal from the continuous or sustained use of a narcotic drug and as a method of bringing the individual to a narcotic
drug-free state within such period.”).
196
Questions
&
Answers,
DRUG
ENFORCEMENT
ADMIN.,
http://
www.deadiversion.usdoj.gov/drugreg/faq.htm (last visited, Feb. 17, 2012).
197
Id.
198
See U.S. DEP’T OF HEALTH & HUMAN SERVS., PUB. NO. SMA 10-4586, RESULTS
FROM THE 2009 NATIONAL SURVEY ON DRUG USE AND HEALTH: VOLUME I. SUMMARY OF
NATIONAL FINDINGS 28 (2010), available at http://www.oas.samhsa.gov/
NSDUH/2k9NSDUH/2k9ResultsP.pdf.
199
Id.
200
Id.
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A. OxyContin Supply Reforms
1.

Disposal

The OxyContin REMS provides that prescribing physicians
201
should advise patients to flush unused tablets down the toilet.
As
noted earlier in this Comment, the REMS is not binding on a physi202
cian and is not used to police physician or patient practices.
The
REMS should be updated to impose more stringent labeling requirements, particularly advising patients of the appropriate disposal
method for unused pills. Currently, the appropriate disposal method
is contained in an eight-page medication guide provided to
203
OxyContin patients.
The disposal instructions should not be buried in such a long, dense document, but rather should be prominently placed on the label. There are, however, many concerns about
204
contamination of the water supply with prescription medications.
Therefore, patients should be encouraged to also use drug take-back
programs to dispose of unused OxyContin.
On October 12, 2010, President Obama signed the Secure and
205
Responsible Drug Disposal Act into law. The Act amends the CSA
to extend to states and private entities the ability to create drug takeback programs, which could provide an additional outlet for the safe
206
disposal of old or unwanted medication. Prior to this law, only law
enforcement authorities could lawfully collect controlled substanc207
es. On September 25, 2010, the DEA conducted a nationwide drug
take-back day, collecting more than 121 tons of medicine at over
208
4,000 collection sites. The new law will permit exploration of these
209
Perhaps doctors’ offices, hospitals, and pharmacies
programs.
should also have a receptacle for medication disposal, which would

201

PURDUE PHARMA, supra note 92, at 33.
Id.
203
PURDUE PHARMA, supra note 96.
204
See MAE WU ET. AL., DOSED WITHOUT PRESCRIPTION: PREVENTING
PHARMACEUTICAL CONTAMINATION OF OUR NATION’S DRINKING WATER 3 (2009), available at http://docs.nrdc.org/health/files/hea_10012001a.pdf.
205
Pub. L. No. 111-273, 124 Stat. 2858 (2010).
206
Carol M. Ostrom & Lauren C. Williams, New State Pain-Medication Law Has Doctors and Patients Nervous, SEATTLE TIMES (Sept. 11, 2010, 12:04 PM),
http://seattletimes.nwsource.com/html/localnews/2012873602_drugs12m.html.
207
Id.
208
Alicia A. Caldwell, DEA Drug Take-Back Nets 121 Tons of Unwanted Drugs,
PRESS,
Oct.
5,
2010,
available
at
ASSOCIATED
http://www.msnbc.msn.com/id/39526659/ns/health-more_health_news/.
209
See H.B. 1121, 2011 Leg., 1st Reg. Sess. (Ind. 2011).
202
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enable a patient to access a proper disposal location without substantially deviating from his or her normal routine or waiting for a drug
210
take-back program day. New Jersey is also exploring secure receptacles, such as refurbished, locked mailboxes at municipal police sta211
tions.
2.

Physician Training

The legal treatment of methadone and buprenorphine emphasizes the importance of practitioner training for the proper dispensing of these drugs. OxyContin prescribers should be required to
meet similar training standards. The OxyContin REMS is insufficient
to ensure that practitioners are properly trained. Although information that the manufacturer provides to practitioners contains useful guidelines, there is no requirement that practitioners follow the
guidelines, or even read the materials before prescribing the medica212
tion. At a minimum, practitioners should have to return the certification form currently enclosed in the REMS materials to be eligible
to prescribe OxyContin. Perhaps a DEA registration-and-waiver
structure similar to that applicable to buprenorphine should also apply to OxyContin. This would allow practitioners with particularized
training in pain management to prescribe OxyContin, and encourage
pain-management patients to pursue care with a practitioner with expertise in relieving pain. This system may help ensure that legitimate
pain sufferers access appropriate care from physicians who meet particularized training requirements. Furthermore, it may be easier for
practitioners who deal with pain patients on a regular basis to differentiate the illegitimate users from the legitimate users.
Finally, health insurers, both private and public, should refuse to
cover prescriptions of OxyContin for ailments other than chronic or
long-term pain. OxyContin was specifically designed to treat patients
213
with around-the-clock moderate-to-severe pain.
Accordingly, doctors should not treat patients suffering from short-term conditions
that require pain suppressing medications with OxyContin.

210

See Bill Would Let Indiana Pharmacies Collect Old Meds, ASSOCIATED PRESS, Jan. 10,
2011, available at http://www.ibj.com/bill-would-let-indiana-pharmacies-collect-oldmeds/PARAMS/article/24511.
211
S. 541, 214th Leg., 2010 Sess. (N.J. 2010).
212
See PURDUE PHARMA, supra note 92, at 35(noting that the completion of the Education Confirmation Form does not affect a practitioner’s ability to prescribe
OxyContin).
213
OxyContin—Questions and Answers, supra note 3.
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3.

State Legislatures and the Washington State Model

State legislatures should act to limit the prescribing of
OxyContin to patients in chronic or long-term pain, for which the
drug is designed. Washington state’s efforts represent one example
of such an initiative. At the beginning of 2010, the Washington State
Legislature introduced, and quickly passed, a bill aimed at curbing
214
the disparate legal treatment of pain relief medications.
Statistics
finding that more Washington residents died from prescription over215
doses than car accidents prompted quick action.
Governor Christine Gregoire signed the bill into law on March 25, 2010; it became
216
effective on June 10, 2010.
The first of its kind in the nation, the law requires the state’s appropriate rulemaking agencies to determine a painmedication dosage level at which practitioners would need to refer patients to pain
217
specialists.
Although the law does not create specific penalties for
failing to adhere to the forthcoming rules, state officials have represented a practitioner who violates the rules will face sanctions from
the state licensing boards that could include losing the right to prac218
tice medicine.
The state adopted voluntary guidelines for practitioners three years ago, but a 2009 survey found that about half of
doctors were unaware of them and many were simply not following
219
them. To strike a balance between facilitating pain relief and creating addiction controls, the law exempts patients with cancer, acute
injury or surgery, or who are in end-of-life care from the new re220
strictions. More states should consider initiatives like Washington’s
and attempt to balance access to pain medication while minimizing
the diversion of pain medication for illicit uses.

B. Reforming the Demand for Addiction-Assistance Medications
In addition to the reforms on the supply side of the issue, reforms must also address the demand side by providing addicts the

214

WASH. REV. CODE § 18.32.785 (2010).
Ostrom & Williams, supra note 206.
216
H.R. 2876, 61st .Leg., Reg. Sess. (Wa. 2010).
217
WASH. REV. CODE § 18.32.785 (2010).
218
Barry Meier, Move to Restrict Pain Killers Puts Onus on Doctors, N.Y. TIMES, July 29,
2010, at B1.
219
Id.
220
Ostrom & Williams, supra note 206.
215
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opportunity to obtain medication to treat their disease. According to
post-marketing surveillance by buprenorphine’s manufacturer, fifty
percent of physicians who are eligible to treat patients with buprenorphine reported that patients who are waiting to get into treatment
221
utilize diverted buprenorphine to treat themselves.
The surveyed
physicians attributed this fact to the insufficient number of physicians
who are eligible to prescribe buprenorphine and to the fact that
222
those physicians are not evenly distributed throughout the country.
223
Accordingly, the patient limit should be eliminated.
The patient
limitations were designed to prevent hundreds of patients from wait224
ing outside doctors’ offices for treatment. Despite patient demand
that outweighs resources, methadone facilities do not suffer from
225
such a problem.
Therefore, it seems overly precautionary to limit
the number of buprenorphine patients. Additionally, practitioners
prescribing buprenorphine need to first demonstrate their training
226
in the treatment of addiction or obtain a special DEA registration.
A physician who chooses to develop expertise in this area should be
allowed to treat as many patients as he or she is capable of treating.
Just as pain-management patients deserve access to their medications
and should consult practitioners with expertise in their ailment, so
too should addicts. Furthermore, nurse practitioners and physician
227
assistants should be able to prescribe buprenorphine.
The policy
reason for restricting nurse practitioners and physician assistants
from prescribing buprenorphine is unclear in light of the fact that
228
they can prescribe other Schedule III drugs.
As the role of nonphysician providers has dramatically increased in the last decade, this
unexplained restriction may further unnecessarily limit access to bu229
prenorphine.
With regard to methadone, despite findings that demonstrate
the effectiveness of maintenance treatment, less than twenty percent
221

Off-Label Use of Buprenorphine for Pain Worries Officials, ALCOHOLISM & DRUG
ABUSE WKLY., Jan. 11, 2010, at 2.
222
Id.
223
For a discussion of patient limits, see supra notes 182–83.
224
Laurie Barclay, New Legislation Increases Number of Patients Allowed for Treatment
with Buprenorphine, MEDSCAPE MED. NEWS (Dec. 20, 2006), http://
www.medscape.com/viewarticle/549706.
225
See Ruth Schubert, Wait for Methadone Puts Hundreds of Lives on Hold, SEATTLE
POST-INTELLIGENCER, Mar. 17, 2003, at A1.
226
See supra text accompanying notes 178–82.
227
See Roose, supra note 190, at 458.
228
Id. at 456.
229
Id. at 456, 459.
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230

of the heroin addicts in the United States use the treatment. Heroin addicts who use maintenance treatment decrease their weekly heroin intake by sixty-nine percent, their criminal activity by fifty-two
percent, and increase their full-time employment by twenty-four per231
cent.
Therefore, the legal structure for methadone should reflect
its positive effects, encouraging use and increasing the availability of
this treatment. Instead, because addicts can only receive this treatment at stand-alone facilities, which are often the subject of local controversy, clinic locations and hours of operation can be inconvenient,
and addicts using the facility may be subject to the negative reactions
232
by the surrounding community. This “can create powerful feelings
of mistrust and alienation and a strong reluctance to seek out or par233
ticipate in programs.”
Furthermore, two states, North Dakota and
234
Wyoming, simply do not have methadone treatment facilities. The
number of facilities in other states varies from one, in Mississippi, to
235
Additional
almost 150, in New York and California respectively.
barriers to access include fees, forms to fill out, referral requirements,
236
and waiting lists.
The law should reflect methadone’s positive effects rather than discourage physicians and addicts from using it in
addiction recovery.
V. CONCLUSION
The legal structure for OxyContin enables a patient to obtain his
or her drug of choice with relative ease because the patient can obtain it through any practitioner at any healthcare facility. But, should
that patient become addicted to OxyContin, he or she will have to
find a practitioner and/or facility that has jumped through several
regulatory hoops to have the power to prescribe a drug to help him
or her combat this addiction.

230
Robert Mathias, NIH Panel Calls for Expanded Methadone Treatment for Heroin AdINST.
DRUG
ABUSE
NOTES
(Nov./Dec.
1997),
diction,
NAT’L
http://archives.drugabuse.gov/NIDA_Notes/NNVol12N6/NIHPanel.html.
231
Id.
232
See CTRS. FOR DISEASE CONTROL AND PREVENTION, SUBSTANCE ABUSE TREATMENT
FOR INJECTION DRUG USERS: A STRATEGY WITH MANY BENEFITS 3 (2002), available at
http://www.cdc.gov/idu/facts/TreatmentFin.pdf.
233
Id.
234
See Opioid Treatment Program Directory, SUBSTANCE ABUSE & MENTAL HEALTH
SERVS. ADMIN., http://dpt2.samhsa.gov/treatment/directory.aspx (last visisted, Jan.
27, 2012) (select “North Dakota” and “Wyoming from” drop down menu).
235
Id. To view the statistics for each state, select “Mississippi”, “New York”, and
“California” from the drop down menu.
236
CTRS. FOR DISEASE CONTROL AND PREVENTION, supra note 232.
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Drug addicts are not a beloved part of society. One need not
search beyond the transcripts from zoning board hearings or news238
paper articles regarding methadone clinics to appreciate this. The
courts have played a role in protecting addicts from discrimination by
invalidating discriminatory zoning actions, but only Congress and the
relevant state and federal agencies can change a legal structure for
medications that discriminates against addicts. This structure has
created a recipe for abusing OxyContin by failing to ensure that physicians are properly trained to dispense OxyContin and by failing to
educate the public on how to properly dispose of pain medications.
But paradoxically, this structure also seems to punish addicts by denying them access to medications proven to assist them in combating
their addiction.
A fear that addicts will abuse drugs, even those designed to help
them, may explain the more stringent regulation of methadone and
buprenorphine. But OxyContin is abused every day. The drug’s time
release properties, the amount of oxycodone contained in the pills,
and the ease with which the pills can be tampered creates a perfect
storm for abuse. The legal structure for OxyContin should reflect
this, and the disparities between the regulations for addictionassistance medications and OxyContin should be rectified through
the creation of more stringent prescription guidelines, better disposal
instructions, and increased physician training.

237

See Americans Want Insurance to Cover Addiction; Unsure if it Does, HAZELDON
FOUND.
(Feb.
3,
2009),
http://www.hazelden.org/web/public/pr090209
healthinsurance.page.
Although 78 percent of Americans recognize that addiction is a chronic disease rather than a moral failing, the words used by those surveyed
when asked to describe people who have problems with drugs or alcohol included: “sinner,” “irresponsible,” “selfish,” “stupid,” “uncaring,”
“loser,” “undisciplined,” “pitiful,” “pathetic,” “weak,” “criminal,” “derelict,” “washed up” and “crazy.” The single highest negative consequence reported of having a family member with a drug problem was
“embarrassment/social stigma.”
Id.
238
See supra note 140, 149–52 and accompanying text.

